PDCD1 and neoplasm: Further, slight anti-tumor effects were observed in four mouse tumor models following genetic ablation of PCSK9, but combination of genetic or pharmacologic inhibition of PCSK9 with anti-PD-1 resulted in robust synergistic effects to increase MHC-I expression and survival and reduce growth of murine melanoma and colorectal carcinoma tumors[227].